Zura Bio Limited (Nasdaq: ZURA) issued a Form 8-K on October 27, 2026, announcing its financial results for the third quarter ended September 30, 2026, and providing updates on its clinical development programs.
The company reported cash and cash equivalents of $187.7 million as of September 30, 2026. Zura stated that this cash balance is expected to fund planned operations through at least the end of 2028.
For the third quarter of 2026, the company recorded a net loss of $25.8 million, or $0.20 per share. This compares to a net loss of $18.0 million, or $0.21 per share, for the same period in 2025. Research and development expenses for the quarter were $19.5 million, up from $11.9 million in the prior year, driven by the execution of Phase 2 clinical programs for tibulizumab and start-up activities for the NEXUS-PMR study. General and administrative expenses for the quarter were $9.3 million, compared to $7.6 million in 2025.
Regarding its clinical pipeline, Zura reported that enrollment has been completed for two Phase 2 studies of its lead candidate, tibulizumab (ZB-106). The TibuSHIELD study in hidradenitis suppurativa enrolled 247 participants, exceeding its target, and topline data is expected in the fourth quarter of 2026. The TibuSURE study in systemic sclerosis enrolled 91 participants, exceeding its target, with topline data expected in the first half of 2027. Additionally, the company confirmed that the NEXUS-PMR study in polymyalgia rheumatica has been cleared by the FDA and is on track to initiate by year-end 2026.
